Filing Flows › Theravance Biopharma (TBPH) › Q4 2024
Theravance Biopharma (TBPH) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 7, 2025
Theravance Biopharma (TBPH) reported revenue of $18.8M for the fourth quarter 2024 (Q4 2024), +7% from a year earlier and +11% from the quarter before. Operating margin was -49.1%, net loss $15.5M (82.8% of revenue).
Theravance Biopharma, Q4 2024: revenue $18.8M (+7% year over year), operating margin -49.1%, net loss $15.5M, operating cash flow −$902K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.8M | +11% | +7% |
| Operating profit | −$9.2M | — | — |
| Net earnings | −$15.5M | — | — |
| Operating cash flow | −$902K | — | — |
What changed
Revenue was $18.8M in Q4 2024, up 7% year over year and up 11% from the previous quarter.
Operating costs exceeded revenue by $9.2M, an operating margin of -49.1%. Total costs grew 17% against revenue growth of 7%. The fastest-growing cost line was SG&A (+19%). The quarter ended with a net loss of $15.5M, wider than the previous quarter's $12.7M loss.
Operating cash flow was −$902K. Non-cash charges added back $5.8M of share-based compensation. Working capital and other items added $8.8M. Capital expenditures of $190K exceeded it, leaving free cash flow of −$1.1M.
Questions
What was Theravance Biopharma's revenue in the fourth quarter 2024?
Theravance Biopharma (TBPH) reported revenue of $18.8M for the fourth quarter 2024 (Q4 2024), +7% from a year earlier and +11% from the quarter before.
Was Theravance Biopharma profitable in the fourth quarter 2024?
Operating loss was $9.2M (-49.1% of revenue) and net loss $15.5M.